BioSpace News Archive

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its third quarter 2021 earnings release and conference call.

Pear Therapeutics, Inc. today announced MassHealth, Massachusetts’ Medicaid program, has notified Pear of its intent to cover Pear’s prescription digital therapeutics (PDTs) reSET® and reSET-O® to fight the growing substance and opioid addiction crisis.

GBS Inc., a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, announced it has filed a Pre-Submission package with the United States Food and Drug Administration.

Veru Inc. (NASDAQ: VERU), today announced that it has enrolled the first patient in its Phase 3 ARTEST registration trial of enobosarm.

Verismo Therapeutics, Inc today announced the appointment of a leading tumor-immunologist and gene-engineered T-cell therapy pioneer, Laura A. Johnson, M.Sc, Ph.D., as its Chief Scientific Officer.

BioLineRx Ltd. today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide

Veracyte, Inc., (Nasdaq: VCYT) announced today the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to chemotherapy prior to radical cystectomy.

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that new independent test data have confirmed the efficacy of a light bulb produced by its wholly owned subsidiary Particle, Inc., in inactivating multiple variants of SARS-CoV-2, the virus that causes COVID-19.

Potrero Medical announced that Steve Okland will join Potrero Medical as Chief Commercial Officer.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has fully accrued the initial planned number of participants in Cohort C (third-line or greater) of its Phase 2 trial studying a combination immunotherapy (Nant Cancer Vaccine) in advanced metastatic pancreatic cancer.